Fintan specialises in tax. He represents companies on tax disputes and the tax issues arising from transactions such as acquisitions, disposals, reorganisations, migrations, securitisations, IP on-shoring and financings.

Fintan advises multinationals, financial institutions and private equity in relation to insurance, financial and structured products in relation to significant tax matters.  He navigates a path for clients through tax disputes, tax litigation and investigations, whether domestic or cross-border.  He is increasingly advising clients on Irish and international policy matters.  Previously, Fintan worked in a City of London law firm and a New York headquartered law firm.

Relevant Experience

  • Running litigation from the Tax Appeals Commission (“TAC”) through all stages to the Irish Supreme Court on issues such as VAT recovery for listed holding companies, management expenses deduction, taxation of share recharge payments, deduction of withholding tax.
  • Advising on MAP and APA processes with the Irish Revenue and tax authorities in the US, UK, Korea, Spain, Canada, among others relating to transfer pricing, residence tie-breaker , non-discrimination, allocation of CEO compensation and other matters.
  • Advising NIQ Global Intelligence plc on its $1.05 billion initial public offering and listing of its ordinary shares on the NYSE.
  • Advising Mallinckrodt plc in relation to its Chapter 11 process, various restructuring matters and its $6.7 billion merger with Endo, Inc.
  • Advising James Hardie on its acquisition of AZEK for a combination of cash and James Hardie shares with a total transaction value of $8.75 billion
  • Advising Aptiv in relation to its accelerated share repurchase transactions, bond issuances and corporate restructurings
  • Representing Barclays Bank Ireland on the sale of its German consumer finance unit to BAWAG estimated to release c. €4.0bn of risk weighted assets or Barclays
  • Representing the first lien creditors to Endo Pharmaceutical in Chapter 11 proceedings
  • Advising CRH on its transition to a US primary listing on the New York Stock Exchange
  • Advising Viatris on the sale of its biosimilars business to Biocon for €3bn
  • Advising Jazz Pharmaceuticals on its proposed acquisition of GW Pharmaceuticals for a total consideration of $7.2 billion
  • Advising Ingersoll Rand on the $15 billion combination of its industrial business with Gardner Denver, the first Reverse Morris Trust involving an Irish Company
  • EU risk retention compliant originator companies and CLOs for Blackstone/GSO, Chenavari, Partners Group, Napier Park, H.I.G and others
  • Advising Shire on the Irish aspects of its acquisition by Takeda Pharmaceutical Company Limited for $62 billion
  • Advising Praxair, Inc. on its $73bn merger of equals with Linde A.G. under a new Irish holding company to be known as Linde plc